Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis.

Technol Cancer Res Treat · 2025 · PMC12174678 · PMID 40525248

Europe PMC DOI

hedged sentences

0.3600

closest p · 7.2× alpha

0.3600

boldest claim

The sentences

showed a trendP = .36not close (p > 0.1)

PARP inhibitors combined with chemotherapy significantly improved PFS (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.63-0.84, P < .0001) and showed a trend towards improved OS (HR 0.93, 95% CI 0.79-1.09, P = .36), though this was not statistically significant.

also in 53,322 other papers

did not reach statistical significanceP = .36not close (p > 0.1)

However, this finding did not reach statistical significance (HR 0.93, 95% CI [0.79, 1.09], P = .36), and no significant heterogeneity was observed (I 2 = 0%, P = .62, Figure 4 ) ( Table S4 ).

also in 111,027 other papers

an increasing trendno p-value reported

38 Moreover, anemia, nausea, and diarrhea significantly increased in all grades of AEs, while grade 3-4 thrombocytopenia showed an increasing trend in the combination group.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.